Inhibrx Biosciences, Inc. · NASDAQ:INBX
Inhibrx Biosciences — Investor Presentation (January 2021)
31 slides from Inhibrx Biosciences's investor presentation, January 2021
Slide 1: Innovation Driven, Outcomes Focused
Innovation Driven Outcomes Focused January 2021
Slide 2: Presentation disclaimer
Presentation disclaimer The Company may not actually achieve the plans, intentions or expectations disclosed in its This presentation contains forward-looking statements. In some cases, you can forward-looking statements, and you should not place undue reliance on the Company’s identify forward-look
Slide 3: Key investment highlights
Key investment highlights Validation from industry Four clinical programs Proprietary single leading partners with upcoming readouts domain antibody (sdAb) platform Potential rapid path Experienced leadership to first approval and team aligned with financial sustainability investors 3
Slide 4: Four differentiated clinical programs addressing large market opportunities
Four differentiated clinical programs addressing large market opportunities !" INBRX-109 INBRX-106 INBRX-105 INBRX-101 Tetravalent DR5 agonist Hexavalent OX40 agonist PD-L1x4-1BB tetravalent AAT-Fc fusion protein + Single agent activity in + Potential across numerous conditional agonist + Potential
Slide 5: Inhibrx's modular sdAb platform
Inhibrx’s modular sdAb platform Versatile and innovative formats enable validated Inhibrx multivalent formats complex target biology to be exploited Precision engineering 75 kDa 90 kDa 105 kDa 120 kDa 135 kDa – Multivalent – precise valency selection engineered to specific target biology – Multispec
Slide 6: INBRX-109
INBRX-109 Tetravalent DR5 Agonist
Slide 7: Death receptor target overview
Death receptor 5 target overview Death receptor 5 (DR5) is a receptor for the tumor necrosis factor-related Valency apoptosis-inducing ligand (TRAIL) 2 4 >4 DR5 activation naturally eliminates damaged and neoplastic cells cancer cancer cancer Apoptosis Higher order clustering of DR5 is required to d
Slide 8: Valency drives DR5-mediated apoptosis
Valency drives DR5-mediated apoptosis Impact of valency on DR5 induced tumor cell death Antibody TRAIL INBRX-109 Tetravalent 100 Anti-DR5 mAb 75 (Bivalent) DR5 DR5 DR5 %Viability TRAIL 50 (Trivalent) 25 INBRX-109 (Tetravalent) 0 cancer cancer cancer 10-5 -4 10 -3 10 10 -2 10-1 1 10 Concentration (nM
Slide 9: INBRX-109 engineered to avoid hepatotoxicity
INBRX-109 engineered to avoid hepatotoxicity Therapeutic format selection designed to balance efficacy and safety Human hepatocyte toxicity assay TAS266 TAS266 INBRX-109 INBRX-109 Hex-1F5 Hepatocytes may be subject to on-target toxicity for DR5 pathway agonism + Previous tetravalent DR5 agonist failed
Slide 10: Ph1 INBRX-109 trial design and status
Ph1 INBRX-109 trial design and status First in human Phase 1 trial started Nov. 2018 PART 1: PART 2: Dose expansion PART 3: Dose escalation cohorts Combination studies completed ongoing initiated 0.3 to 30 mg/kg Aug. 2019 Initial expansion cohort indications were selected based on in vitro and 20 Pa
Slide 11: Fast to market opportunity
Fast to market opportunity Chondrosarcoma Incidence rate PFS from failed study of ~1 in 200,000 persons per year Therapeutic IPI-926 (HH) Control arm Placebo Subject number 100 (2:1) ~1,400 Efficacy data PFS 3.7 mo vs 2.9 mo Placebo cases per year Comment Negative study No approved therapeutic for t
Slide 12: INBRX-109 data and registration-enabling study design in chondrosarcoma
INBRX-109 data and registration-enabling study design in chondrosarcoma INBRX-109 in chondrosarcoma: Potential registration-enabling study design: Randomized, double-blind, placebo-controlled, Phase 2 study of INBRX-109 as any-line therapy in unresectable or metastatic conventional chondrosarcoma Ra
Slide 13: INBRX-109 potential in multiple indications
INBRX-109 potential in multiple indications FUTURE POTENTIAL OPPORTUNITIES Solid tumors STUDIES INITIATED + IAP antagonists IN Q3 OF 2020 Hematologic tumors INITIAL INDICATIONS Pancreatic – 2nd line + Bcl-2 inhibitors FOLFIRI Chondrosarcoma NSCLC Registration-enabling study Mesothelioma + various co
Slide 14: INBRX-106
INBRX-106 Hexavalent OX40 Agonist
Slide 15: INBRX-106 hexavalent OX40 agonist
INBRX-106 hexavalent OX40 agonist OX40 is a co-stimulatory receptor on activated T-cells OX40: sdAb OX40: sdAb Hexavalent engagement of OX40: • Provides co-stimulation to activated T-cells OX40: sdAb OX40: sdAb • Reverses regulatory T-cell induced immune suppression OX40: sdAb OX40: sdAb • Enhances
Slide 16: INBRX-106 is a best-in-class OX40 agonist
INBRX-106 is a best-in-class OX40 agonist Valency Isotype Ligand blocking Candidates Status MOXR-0916 Discontinued GSK-3174998 Ph 1 (MM, 2019) BMS-986178 Ph 1 (2016) Bi- IgG1 Y INCAGN-1949 Ph 1 (2016) ABBV-368 Ph 1 (HNSCC, 2020) IBI-101 Ph 1 (2018) MEDI-0562 Discontinued Bi- IgG2 Y PF-04518600 Disco
Slide 17: Hexavalent OX40 agonism potently induces anti-tumor immune activation
Hexavalent OX40 agonism potently induces anti-tumor immune activation Redmond lab Earle A. Chiles Research Institute Providence Cancer Institute Hexavalent OX40 agonism impacts multiple cell populations to tip the balance toward tumor eradication 17
Slide 18: Phase 1 INBRX-106 trial design and status
Phase 1 INBRX-106 trial design and status Initial data from Part 1 - Dose escalation in combination with Keytruda™ initiated PARTS 1 & 3: - Signs of single agent activity, including prior PD-1 failures PARTS 2 & 4: Dose escalation - 0.03 mg/kg dose selected based on rapid loss of OX40, memory T cell
Slide 19: INBRX-105
INBRX-105 PD-L1 x 4-1BB Multispecific
Slide 20: INBRX-105 tumor-targeted 4-1BB agonist
INBRX-105 tumor-targeted 4-1BB agonist 41BB agonism boosts anti-tumor T-cell activity PD-L1: sdAb INBRX-105, a PD-L1 dependent 4-1BB agonist: • Provides potent PD-1/PD-L1 blockade • 4-1BB agonism only at sites of PD-L1 expression, 4-1BB: sdAb provides local co-stimulation to TILs • Engineered to avo
Slide 21: INBRX-105 reversed suppression by PD-L1
INBRX-105 reversed suppression by PD-L1 Anti-PD-L1 Anti-PD-L1 INBRX-105 potently reversed PD-L1/PD-1 MCLA-145 analog* suppression with activity equivalent to displayed ~20 fold Tecentriq® in preclinical assay reduction in potency Cell based PD-1/PD-L1 blockade assay: artificial Data indicated potent
Slide 22: Phase 1 INBRX-105 trial design and status
Phase 1 INBRX-105 trial design and status First in human Phase 1 trial started Feb. 2019 PART 1: PART 2: PART 3: PART 4: Dose escalation Dose expansion Dose escalation Dose expansion ongoing planned planned planned INBRX-105 INBRX 105 INBRX-105 + Keytruda™ INBRX-105 + Keytruda™ Locally advanced or 2
Slide 23: INBRX-101
INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein
Slide 24: AATD and current therapy shortcomings
AATD and current therapy shortcomings What is AATD? AATD standard of care AATD is an orphan respiratory Current therapy is sub-optimal inherited disease Plasma derived AAT with weekly infusions is Increases risk of developing pulmonary not able to maintain normal serum AAT levels disease, resulting
Slide 25: INBRX-101 optimizing AAT augmentation therapy
INBRX-101 optimizing AAT augmentation therapy Elimination of oxidation-prone residues INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein AAT • Potential to extend the dosing range, from weekly to every three weeks, while maintaining patients in the normal range of AAT exposu
Slide 26: INBRX-101: first human pharmacokinetic data
INBRX-101: first human pharmacokinetic data PK profile of first 5 patients: 10 mg/kg INBRX-101 10 Serum AAT level (μM) Preliminary human PK data for first five subjects dosed with 10 mg/kg single IV dose of INBRX-101 1 • Consistent with preclinical estimates • Estimated human half-life is approximat
Slide 27: Near term expected clinical milestones
Near term expected clinical milestones INBRX-101 (AAT) Phase 1 data INBRX-105 (PDL-1x41BB) expansion cohort data INBRX-109 (DR5) initial combination study data INBRX-106 (OX40) / Keytruda dose escalation cohort data INBRX-109 (DR5) registration-enabling trial initiation- chondrosarcoma INBRX-105 (PD
Slide 28: Inhibrx contact details
11025 N. Torrey Pines Rd, Ste 140 La Jolla, CA 92037 www.inhibrx.com
Slide 29: Supplementary Slides
Supplementary Slides
Slide 30: INBRX-109 data in malignant pleural mesothelioma
INBRX-109 data in malignant pleural mesothelioma Cut point 17-Oct-2020, study ongoing Disclaimer: Per investigator assessments, not confirmed by central radiology review, and data subject to change PR=Partial Response, SD=Stable Disease, PD=Progressive Disease, NE=Not Evaluable ► Ongoing 30 *Off-stu
Slide 31: INBRX-109 - favorable Adverse Event (AE) profile
INBRX-109 - favorable Adverse Event (AE) profile AE Term AE related to INBRX-109 (very likely, probable, possible) Grade per CTCAEv5.0 Gr1&2 (N) Gr1&2 (%) Gr=/>3 (N) Gr=/>3 (%) All Grade (N) All Grade (%) Fatigue 14 18 0 0 14 18 AST increased 7 9 3 4 10 13 ALT increased 7 9 3 4 10 13 Nausea 6 8 1 1